Great Point Partners LLC 89bio, Inc. Transaction History

Great Point Partners LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $2.62 Million - $4.24 Million	250,000 New	250,000 $3.81 Million
Q3 2022 Nov 14, 2022	SELL	$3.02 - $7.0 $1.34 Million - $3.12 Million	-445,000 Reduced 31.79%	955,000 $5.53 Million
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $2.93 Million - $5.63 Million	1,400,000 New	1,400,000 $4.51 Million

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $387M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.